This OS advantage was also observed in EGFR-mutated adenocarcinomas (36.7 vs. 27.2 months; HR 0.76, 95% CI: 0.66–0.87, p < 0.001) (Figure 2c). The gene discussed is EGFR; the disease is adenocarcinoma.